Sickle cell anemia in the female patient

Nathalie Dauphin-McKenzie, Jerry M. Gilles, Elvire Jacques, Thomas Harrington

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Seventy-two thousand Americans are homozygous for the sickle cell gene and 2 million are carriers. The gene offers protection against malaria but can be a cause of chronic pain and early death. Life expectancy is 48 years for females. Some people with sickle cell anemia live into their 60s and beyond. The purpose of this article is to review and summarize evidence from clinical, translational, and epidemiologic studies that have examined the clinically relevant aspects of sickle cell anemia as it relates to the female patient. Studies were identified through a MEDLINE search for articles in English between the years 1966 and 2005. References from identified reports were also used to identify additional articles. Women with sickle cell disease experience multiple complications. These complications can affect each and every organ system and are often worse in pregnant women. Progestins, hydroxyurea, and bone marrow transplant appear to ameliorate sickle cell anemia. Other therapies being evaluated include those that increase fetal hemoglobin concentration and prevent dehydration of the sickle red blood cells. More than one third of pregnancies in women with sickle syndromes terminate in abortion, stillbirth, or neonatal death. Recently, a number of genes modifying the clinical severity of sickle cell anemia have been identified. Sickle anemia is associated with immense suffering and multisystemic complications. In addition to the now-established therapy with hydroxyurea and bone marrow transplants, there are multiple investigational treatments that offer the hope of extending life expectancy while diminishing associated morbidities. Whether any of these new agents are safe in pregnancy has yet to be determined.

Original languageEnglish
Pages (from-to)343-352
Number of pages10
JournalObstetrical and Gynecological Survey
Volume61
Issue number5
DOIs
StatePublished - May 1 2006

Fingerprint

Sickle Cell Anemia
Hydroxyurea
Life Expectancy
Hope
Bone Marrow
Genes
Transplants
Fetal Hemoglobin
Pregnancy
Investigational Therapies
Stillbirth
Progestins
Dehydration
Psychological Stress
MEDLINE
Chronic Pain
Malaria
Anemia
Pregnant Women
Epidemiologic Studies

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Sickle cell anemia in the female patient. / Dauphin-McKenzie, Nathalie; Gilles, Jerry M.; Jacques, Elvire; Harrington, Thomas.

In: Obstetrical and Gynecological Survey, Vol. 61, No. 5, 01.05.2006, p. 343-352.

Research output: Contribution to journalArticle

Dauphin-McKenzie, Nathalie ; Gilles, Jerry M. ; Jacques, Elvire ; Harrington, Thomas. / Sickle cell anemia in the female patient. In: Obstetrical and Gynecological Survey. 2006 ; Vol. 61, No. 5. pp. 343-352.
@article{c358ad0691c847508ad23600937b2e30,
title = "Sickle cell anemia in the female patient",
abstract = "Seventy-two thousand Americans are homozygous for the sickle cell gene and 2 million are carriers. The gene offers protection against malaria but can be a cause of chronic pain and early death. Life expectancy is 48 years for females. Some people with sickle cell anemia live into their 60s and beyond. The purpose of this article is to review and summarize evidence from clinical, translational, and epidemiologic studies that have examined the clinically relevant aspects of sickle cell anemia as it relates to the female patient. Studies were identified through a MEDLINE search for articles in English between the years 1966 and 2005. References from identified reports were also used to identify additional articles. Women with sickle cell disease experience multiple complications. These complications can affect each and every organ system and are often worse in pregnant women. Progestins, hydroxyurea, and bone marrow transplant appear to ameliorate sickle cell anemia. Other therapies being evaluated include those that increase fetal hemoglobin concentration and prevent dehydration of the sickle red blood cells. More than one third of pregnancies in women with sickle syndromes terminate in abortion, stillbirth, or neonatal death. Recently, a number of genes modifying the clinical severity of sickle cell anemia have been identified. Sickle anemia is associated with immense suffering and multisystemic complications. In addition to the now-established therapy with hydroxyurea and bone marrow transplants, there are multiple investigational treatments that offer the hope of extending life expectancy while diminishing associated morbidities. Whether any of these new agents are safe in pregnancy has yet to be determined.",
author = "Nathalie Dauphin-McKenzie and Gilles, {Jerry M.} and Elvire Jacques and Thomas Harrington",
year = "2006",
month = "5",
day = "1",
doi = "10.1097/01.ogx.0000216976.15100.29",
language = "English",
volume = "61",
pages = "343--352",
journal = "Obstetrical and Gynecological Survey",
issn = "0029-7828",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Sickle cell anemia in the female patient

AU - Dauphin-McKenzie, Nathalie

AU - Gilles, Jerry M.

AU - Jacques, Elvire

AU - Harrington, Thomas

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Seventy-two thousand Americans are homozygous for the sickle cell gene and 2 million are carriers. The gene offers protection against malaria but can be a cause of chronic pain and early death. Life expectancy is 48 years for females. Some people with sickle cell anemia live into their 60s and beyond. The purpose of this article is to review and summarize evidence from clinical, translational, and epidemiologic studies that have examined the clinically relevant aspects of sickle cell anemia as it relates to the female patient. Studies were identified through a MEDLINE search for articles in English between the years 1966 and 2005. References from identified reports were also used to identify additional articles. Women with sickle cell disease experience multiple complications. These complications can affect each and every organ system and are often worse in pregnant women. Progestins, hydroxyurea, and bone marrow transplant appear to ameliorate sickle cell anemia. Other therapies being evaluated include those that increase fetal hemoglobin concentration and prevent dehydration of the sickle red blood cells. More than one third of pregnancies in women with sickle syndromes terminate in abortion, stillbirth, or neonatal death. Recently, a number of genes modifying the clinical severity of sickle cell anemia have been identified. Sickle anemia is associated with immense suffering and multisystemic complications. In addition to the now-established therapy with hydroxyurea and bone marrow transplants, there are multiple investigational treatments that offer the hope of extending life expectancy while diminishing associated morbidities. Whether any of these new agents are safe in pregnancy has yet to be determined.

AB - Seventy-two thousand Americans are homozygous for the sickle cell gene and 2 million are carriers. The gene offers protection against malaria but can be a cause of chronic pain and early death. Life expectancy is 48 years for females. Some people with sickle cell anemia live into their 60s and beyond. The purpose of this article is to review and summarize evidence from clinical, translational, and epidemiologic studies that have examined the clinically relevant aspects of sickle cell anemia as it relates to the female patient. Studies were identified through a MEDLINE search for articles in English between the years 1966 and 2005. References from identified reports were also used to identify additional articles. Women with sickle cell disease experience multiple complications. These complications can affect each and every organ system and are often worse in pregnant women. Progestins, hydroxyurea, and bone marrow transplant appear to ameliorate sickle cell anemia. Other therapies being evaluated include those that increase fetal hemoglobin concentration and prevent dehydration of the sickle red blood cells. More than one third of pregnancies in women with sickle syndromes terminate in abortion, stillbirth, or neonatal death. Recently, a number of genes modifying the clinical severity of sickle cell anemia have been identified. Sickle anemia is associated with immense suffering and multisystemic complications. In addition to the now-established therapy with hydroxyurea and bone marrow transplants, there are multiple investigational treatments that offer the hope of extending life expectancy while diminishing associated morbidities. Whether any of these new agents are safe in pregnancy has yet to be determined.

UR - http://www.scopus.com/inward/record.url?scp=33646771775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646771775&partnerID=8YFLogxK

U2 - 10.1097/01.ogx.0000216976.15100.29

DO - 10.1097/01.ogx.0000216976.15100.29

M3 - Article

C2 - 16635275

AN - SCOPUS:33646771775

VL - 61

SP - 343

EP - 352

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

SN - 0029-7828

IS - 5

ER -